Viewing Study NCT04468061


Ignite Creation Date: 2025-12-24 @ 12:12 PM
Ignite Modification Date: 2026-01-29 @ 6:23 PM
Study NCT ID: NCT04468061
Status: RECRUITING
Last Update Posted: 2025-12-05
First Post: 2020-07-08
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Sponsor: Dana-Farber Cancer Institute
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Breast Cancer View
None Triple Negative Breast Cancer View
None PD-L1 Negative View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Breast Cancer View
None Triple Negative Breast Cancer View
None PD-L1 Negative View